The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors

MLA

Domenica Lorusso, et al. “The GATTO Study: A Phase I of the Anti-MUC1 Gatipotuzumab (GAT) in Combination with the Anti-EGFR Tomuzotuximab (TO) in Patients with EGFR Positive Solid Tumors.” Journal of Clinical Oncology, vol. 36, May 2018, p. TPS2596. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........476c637f432840abfbaf6ceb88c0600f&authtype=sso&custid=ns315887.

APA

Domenica Lorusso, Elena Garralda, Ignacio Matos, Ulrich Keilholz, Alfredo Zurlo, Josep Tabernero, Riccardo Belli, Hans Baumeister, Maxim Kebenko, Gianluca Del Conte, Luca Gianni, Konrad Klinghammer, Christina Dicke, Francesco Raspagliesi, Beate Habel, Walter Fiedler, & Sebastian Ochsenreither. (2018). The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors. Journal of Clinical Oncology, 36, TPS2596.

Chicago

Domenica Lorusso, Elena Garralda, Ignacio Matos, Ulrich Keilholz, Alfredo Zurlo, Josep Tabernero, Riccardo Belli, et al. 2018. “The GATTO Study: A Phase I of the Anti-MUC1 Gatipotuzumab (GAT) in Combination with the Anti-EGFR Tomuzotuximab (TO) in Patients with EGFR Positive Solid Tumors.” Journal of Clinical Oncology 36 (May): TPS2596. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........476c637f432840abfbaf6ceb88c0600f&authtype=sso&custid=ns315887.